A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Recruiting
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
12/07/2023
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Alzheimer's Disease
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Recruiting
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-552 is in treating sy... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
12/04/2023
Locations: Allied Physicians - Fort Wayne Neurological Center /ID# 248300, Fort Wayne, Indiana +1 locations
Conditions: Alzheimer's Disease (AD)
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
Recruiting
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia. MCI impacts 12-18% of people in the United States over age 60 years (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https://www.alz.org/alzheimers-dementia/what-is-dementia/related_conditions/mild-cognitive-impairment. Accessed August 16, 2022). MCI does not substantially interfere with daily activities, although complex... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
12/01/2023
Locations: Josephson Wallack Munshower Neurology, P.C., Indianapolis, Indiana
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
11/30/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Alzheimer's Disease Neuroimaging Initiative 4
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
11/30/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
TRC-PAD Program: In-Clinic Trial-Ready Cohort
Recruiting
The purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to in-clinic evaluation and biomarker confirmation. Participants with known biomarker status may have direct referral to the Trial-Ready Cohort. If you are interested in being selected for the TRC-PAD study, you should first enroll in the APT Webstudy (https://www.aptwebstud... Read More
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
11/30/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
Recruiting
The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of E2814 on microtubule binding region (MTBR)-tau species in cerebrospinal fluid (CSF) in participants with DIAD.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/29/2023
Locations: Indiana University School of Medicine, Health Partners, Adult Neurology Clinic, Indianapolis, Indiana
Conditions: Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single intrathecal (IT) doses of ALN-APP in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment for Part B: 12 months.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/14/2023
Locations: Clinical Trial Site, Indianapolis, Indiana
Conditions: Early-Onset Alzheimer Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
Recruiting
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed across three cohorts: (1) early onset Alzheimer's Disease (EOAD) participants, (2) early onset non-Alzheimer's Disease (EOnonAD) participants, and (3) cognitively normal (CN) control participants.
Gender:
All
Ages:
Between 40 years and 64 years
Trial Updated:
11/06/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)
Recruiting
This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's disease. Approximately 530 subjects will be randomized to 12 months of daily treatment with either Active or Sham Sensory Stimulation Systems. Efficacy will be measured using the Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) assessment and a combined statistical test (CST) of the ADCS-ADL and the Mini-Mental State E... Read More
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
11/06/2023
Locations: Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana
Conditions: Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Trial-Ready Cohort-Down Syndrome (TRC-DS)
Recruiting
The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 250 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-DS) study. Participants enrolled in the TRC-DS will undergo longitudinal cognitive and clinical assessment, genetic and biomarker testing, as well as imaging and biospecimen collection. Using these outc... Read More
Gender:
All
Ages:
Between 25 years and 55 years
Trial Updated:
10/21/2023
Locations: Indiana University, Indianapolis, Indiana
Conditions: Down Syndrome, Alzheimer Disease, Dementia
Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease
Recruiting
This study is an RCT to evaluate the effectiveness of Brain Safe on reducing anticholinergic exposure. Over 42 months, the trial will enroll 700 community-dwelling older adults who were prescribed one or more strong anticholinergics. Participants will be randomized to use the Brain Safe app or an attention control medication list app for 12 months, with monthly usage reminders.
Gender:
All
Ages:
60 years and above
Trial Updated:
10/20/2023
Locations: IU Health, Indianapolis, Indiana +1 locations
Conditions: Alzheimer Disease, Dementia